[Clinical studies on the tolerance of a new antibiotic combination, pivampicillin and dicloxacillin].
The tolerance of a new pivampicillin and dicloxacillin association, especially at high doses and during prolonged treatment, was assessed by administering two 600 mg tablets (350 mg pivampicillin + 250 mg dicloxacillin) every 6 or 8 hr (according to the seriousness of the diseases) to 53 patients with acute infection of varying site and aetiology. Microbiological, radiological and blood chemistry data were collected with reference to the disease involved, along with clinical and laboratory data capable of demonstrating the eventual appearance of unwanted side-effects referable to the association. The results showed that the association was therapeutically effective and well tolerated at high doses given over long periods.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000031:analogs & derivatives*; D001424:Bacterial Infections / Q000188:drug therapy; D002644:Chickenpox / Q000188:drug therapy; D002648:Child; D002986:Clinical Trials as Topic; D004009:Dicloxacillin / Q000627:therapeutic use*; D004338:Drug Combinations; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006525:Hepatitis, Viral, Human / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010917:Pivampicillin / Q000627:therapeutic use*
D004338:Drug Combinations; D010917:Pivampicillin; D000667:Ampicillin; D004009:Dicloxacillin
Indagine clinica sulla tollerabilità di una nuova associazione antibiotica, pivampicillina e dicloxacillina